ES2136139T3 - Componente farmaceutico de accion ralentizada que contiene acido bilico como componente activo. - Google Patents

Componente farmaceutico de accion ralentizada que contiene acido bilico como componente activo.

Info

Publication number
ES2136139T3
ES2136139T3 ES94106838T ES94106838T ES2136139T3 ES 2136139 T3 ES2136139 T3 ES 2136139T3 ES 94106838 T ES94106838 T ES 94106838T ES 94106838 T ES94106838 T ES 94106838T ES 2136139 T3 ES2136139 T3 ES 2136139T3
Authority
ES
Spain
Prior art keywords
component
slow action
action containing
pharmaceutical
active component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106838T
Other languages
English (en)
Inventor
Fabio Borella
Alberto Brandt
Fabio Carli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Biochimico Italiano Giovanni Lorenzini SpA
Original Assignee
Istituto Biochimico Italiano Giovanni Lorenzini SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Biochimico Italiano Giovanni Lorenzini SpA filed Critical Istituto Biochimico Italiano Giovanni Lorenzini SpA
Application granted granted Critical
Publication of ES2136139T3 publication Critical patent/ES2136139T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBE UNA COMPOSICION FARMACEUTICA DE BAJA LIBERACION QUE CONTIENE ACIDO DE BILIS COMO INGREDIENTE ACTIVO Y QUE COMPRENDE AL MENOS UNA SUBSTANCIA BIOADHESIVA Y UNA SUBSTANCIA DE ELEVADA GRAVEDAD ESPECIFICA, TENIENDO LA MITAD CON CUBIERTA ENTERICA Y EL RESTO CON CUBIERTA NO ENTERICA.
ES94106838T 1993-05-18 1994-05-02 Componente farmaceutico de accion ralentizada que contiene acido bilico como componente activo. Expired - Lifetime ES2136139T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93MI001014A IT1265074B1 (it) 1993-05-18 1993-05-18 Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare

Publications (1)

Publication Number Publication Date
ES2136139T3 true ES2136139T3 (es) 1999-11-16

Family

ID=11366211

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106838T Expired - Lifetime ES2136139T3 (es) 1993-05-18 1994-05-02 Componente farmaceutico de accion ralentizada que contiene acido bilico como componente activo.

Country Status (5)

Country Link
US (1) US5510114A (es)
EP (1) EP0625353B1 (es)
DE (1) DE69419365T2 (es)
ES (1) ES2136139T3 (es)
IT (1) IT1265074B1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US20070092454A1 (en) * 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
US8119162B2 (en) 2005-11-10 2012-02-21 Colgate-Palmolive Company Particles that disrupt or impede bacterial adhesion, related compositions and methods
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
CN104039327B (zh) * 2012-01-06 2017-02-15 大熊制药株式会社 含有牛磺熊去氧胆酸的组合物
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
MX2022001865A (es) * 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918411A (en) * 1957-11-01 1959-12-22 Olin Mathieson Pharmaceutical preparations
IT1101649B (it) * 1978-12-15 1985-10-07 Lehner Ag Composizione farmaceutica ad azione prolungata contenente acidi biliari
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
IT1249686B (it) * 1991-07-22 1995-03-09 Boniscontro E Gazzone S R L Preparazioni farmaceutiche orali, a base di acidi biliari, a cessione protratta e controllata con le quali e' possibile adottare una sola somministrazione giornaliera
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids

Also Published As

Publication number Publication date
EP0625353A1 (en) 1994-11-23
DE69419365D1 (de) 1999-08-12
ITMI931014A0 (it) 1993-05-18
DE69419365T2 (de) 2000-03-30
US5510114A (en) 1996-04-23
IT1265074B1 (it) 1996-10-30
EP0625353B1 (en) 1999-07-07
ITMI931014A1 (it) 1994-11-18

Similar Documents

Publication Publication Date Title
BR0215052A (pt) Composições acaricidas e métodos
PT650476E (pt) Agente vasodilatador periferico que contem derivados n-acilados de 4-amino-piperidina como ingredientes activos
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
CO4750758A1 (es) Compuestos de 5-amino-4-etilsulfinil-1-arilpirazol, composiciones que los contienen y procedimiento para su preparacion
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
ES2059841T3 (es) Nitro compuestos con actividad insecticida.
BR0300949A (pt) Composto de éster e seu uso
ES2196092T3 (es) Composicion antibacteriana liposomica, de baja rigidez.
BR9306460A (pt) Novo uso de hexaflumuron e compostos relacionados como termiticidas
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
DE60027575D1 (de) Verwendung von Spinosad oder einer Zusammensetzung enthaltend spinosad
ES2116642T3 (es) Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol.
ATE15596T1 (de) Pharmazeutische mittel.
ES2046176T3 (es) Composicion farmaceutica que contiene una asociacion de colageno y de un principio activo antiseptico y/o antiinflamatorio y su procedimiento de fabricacion.
PT89534A (pt) Processo para a preparacao de composicoes farmaceuticas anticoagulantes contendo como ingrediente activo proteina c ou proteina c activada combinada com heparina
BR0111678A (pt) Composições medicinais contendo derivados de propenona
BR9707247A (pt) Diidrobenzofurano e compostos relacionados úteis como agentes antiinflamatórios
FI911863A7 (fi) Metyleenidifosfonihappoyhdiste ja tulehdusta estävä aine, joka sisältä ä tätä yhdistettä tehokomponenttina
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ES2145360T3 (es) Sales cristalinas y estables de acido tetrahidrofolico.
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
ES2196049T3 (es) Uso de 2-(2-alquilfenilamino)oxazolinas y -tiazolinas para la fabricacion de un medicamento con efecto alfa 2 adrenergico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625353

Country of ref document: ES